DYAI
Dyadic International, Inc.
There isn't enough reported data to score DYAI yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DYAI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
DYAI's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DYAI PE Valuation
DYAI has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DYAI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect DYAI's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DYAI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.21 | -$0.02 |
| Q1 2026 | -$0.21 | -$0.01 |
| Q4 2025 | -$0.23 | -$0.03 |
| Q3 2025 | -$0.24 | -$0.02 |
| Q2 2025 | -$0.19 | +$0.08 |
| Q1 2025 | -$0.20 | +$0.07 |
| Q4 2024 | -$0.20 | +$0.03 |
| Q3 2024 | -$0.22 | +$0.01 |
DYAI is still losing money, but far less than before: $0.21 per share over the past year, against $0.47 at its worst in late 2021.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DYAI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $961.1K | -0.6% |
| Q1 2026 | $1.1M | +182% |
| Q4 2025 | $565.5K | -31% |
| Q3 2025 | $1.2M | -41% |
| Q2 2025 | $966.6K | +150% |
| Q1 2025 | $393.6K | +18% |
| Q4 2024 | $817.4K | +19% |
| Q3 2024 | $2M | +393% |
DYAI's revenue has slid since its 2024 peak: $961,138 last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -214% | -35 points |
| Q1 2026 | -171% | +338 points |
| Q4 2025 | -272% | -84 points |
| Q3 2025 | -165% | -155 points |
| Q2 2025 | -179% | +350 points |
| Q1 2025 | -509% | +126 points |
| Q4 2024 | -187% | +129 points |
| Q3 2024 | -10% | +423 points |
DYAI's operating margin was −214% last quarter, down 35 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DYAI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over DYAI on profitability, with a higher operating margin.
DYAI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.8M | -$1.7M |
| Q1 2026 | -$2M | -$13.6K |
| Q4 2025 | -$1.8M | -$1.1M |
| Q3 2025 | -$1.9M | -$1.7M |
| Q2 2025 | -$130K | +$1.8M |
| Q1 2025 | -$1.9M | -$836.8K |
| Q4 2024 | -$696.4K | +$227K |
| Q3 2024 | -$201.1K | +$1.8M |
DYAI has burned cash in almost every quarter: −$7M over the past year, against −$3M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over DYAI on cash generation, producing positive trailing cash flow while its opponent burns cash.
DYAI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +40.7K shares |
| 1 year | +21% | +6.3M shares |
| 3 years | +26% | +7.6M shares |
| 5 years | +32% | +8.8M shares |
| Available history | +34% | +9.3M shares |
DYAI has 36M diluted shares, up 21% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
| Q3 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DYAI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DYAI Net Leverage
DYAI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DYAI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.7 | Neutral |
| Stochastic | 2.7 | Oversold |
DYAI's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DYAI PE vs Healthcare Sector
DYAI has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DYAI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.40 | 13% below |
| 20 week MA | $0.66 | 47% below |
| 50 week MA | $0.77 | 55% below |
| 100 week MA | $0.98 | 64% below |
| 200 week MA | $1.30 | 73% below |
DYAI is in a downtrend: it's below all five of its weekly moving averages, and 73% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DYAI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.28 | $5.57 | +5.5% |
| 2021 | $5.57 | $4.11 | -26% |
| 2022 | $4.11 | $1.37 | -67% |
| 2023 | $1.37 | $1.61 | +18% |
| 2024 | $1.61 | $1.96 | +22% |
| 2025 | $1.96 | $0.95 | -52% |
| 2026 YTD | $0.95 | $0.35 | -63% |
DYAI has finished lower in three of the last six years. It's down 63% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over DYAI on returns for 2026, with the stronger performance.